Clinical Trial Update: Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tislelizumab plus chemotherapy followed by surgery versus upfront surgery in resectable, clinically node-negative head and neck squam…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• tislelizumab (Tivdak) (tislelizumab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING